Individualized Weight Loss
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
Your Ivím GLP-1 ID Patient Journey
Here’s how it works:
What your individual program includes
Competitors
Medicine
ONLY
$850 value
coaching & community
$500 value
formulated supplements
Ivím Health App
What to Expect
Your Ivím GLP-1 ID Patient Journey
Understanding individualized compounded GLP-1 medications
Learn more about GLP-1s
-
What to Know About Compounding Pharmacies Before You Buy Peptides Online
If you’ve spent time researching peptide therapy, you’ve probably already found places to buy peptides without a prescription. They’re not hard to find. The compounds are often sold as research chemicals, with disclaimers that they’re not for human use, and the prices are accessible. What’s harder to find […]
-
Why Physician Oversight Doesn’t Mean Higher Prices
There is a persistent worry in the peptide community that physician involvement will make everything more expensive and less accessible. It’s understandable. Healthcare in this country has a long track record of adding cost and friction without adding proportional value. The […]
-
Is Peptide Therapy Right for You? How a Medical Care Provider Actually Evaluates It
The question isn’t whether peptides work. For many people, in the right context, they do. The question is whether they’re right for you — and answering that requires more than a protocol borrowed from someone online. The First Thing We Look […]
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
*Based on our internal data and individual patient outcomes may vary. This does not constitute a guarantee of specific results.
✝ These results include data from patients using both FDA-approved and compounded formulations.
Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes



